Youden’s test of the chromatographic determination of captopril in pharmaceuticals

Liliya Logoyda1*, Yuliya Kondratova2, Dmytro Korobko1, Oleksandr Susla3, Yuriy Soroka4, Roman Tsytsiura5, Svitlana Pidruchna6

1Department of Pharmaceutical Chemistry, I. Horbachevsky Ternopil State Medical University, Ukraine, 2Central R&D Laboratory JSC Farmak, Ukraine, 3Department of Emergency Medical Aid and Emergency Medical Treatment, I. Horbachevsky Ternopil State Medical University, Ukraine, 4Department of Anaesthesiology and Intensive-Care Medicine, I. Horbachevsky Ternopil State Medical University, Ukraine, 5Department of Disaster of Medicine Catastroph and Military Medicine, I. Horbachevsky Ternopil State Medical University, Ukraine, 6Department of Medical Biochemistry, I. Horbachevsky Ternopil State Medical University, Ukraine

Abstract

Introduction: Robustness tests were originally introduced to avoid problems in interlaboratory studies and to identify the potentially responsible factors. This means that a robustness test was performed at a late stage in the method validation since interlaboratory studies are performed in the final stage. Thus, the robustness test was considered a part of method validation related to the precision (reproducibility) determination of the method. However, performing a robustness test late in the validation procedure involves the risk that when a method is found not to be robust, it should be redeveloped and optimized. At this stage, much effort and money have already been spent in the optimization and validation, and therefore one wants to avoid this. The aim of this study was to evaluate the robustness of ultra-high-performance liquid chromatography (UHPLC) determination of captopril in tablets using Youden’s test. Materials and Methods: An efficient method to assess the robustness of analytical methods is by Youden’s test, by means of an experiment design which involves seven analytical parameters combined in eight tests. In the recent studies, we assessed the robustness of a chromatographic method to quantify captopril in tablets using Youden’s test. Results: Using the Youden’s test criteria, UHPLC method showed to be greatly robust concerning captopril content, at the introduction of variation in seven analytic parameters. The highest variation in captopril content was 0.96%, when was used column Nucleosil C18 (4.6 mm × 150 mm with a particle size of 5 μ). Using column Ascentis Express C18 Fused-Core® technology (column size 4.6 mm × 150 mm with a particle size of 5 μ) reduces the retention time of captopril more than 2 times. Conclusion: Youden’s test proved to be an efficient and helpful tool for the robustness evaluation for assay of captopril by UHPLC.

Key words: Captopril, quantitative analysis, robustness, ultra-high-performance liquid chromatography, Youden’s test

INTRODUCTION

Robustness testing is in recent time best known and most commonly only used in the pharmaceutical world because of the stringent regulations in that domain set by regulatory authorities which require extensively validated methods. Therefore, most definitions and existing methodologies, for example, those from the ICH, can be found in that field, as one can observe from the above. Although this has no implications for robustness testing of analytical methods in other domains and this guideline is therefore not confined to pharmaceutical methods.[1]

Address for correspondence:
Liliya Logoyda, Department of Pharmaceutical Chemistry, I. Horbachevsky Ternopil State Medical University, Ukraine.
E-mail: logojda@tdmu.edu.ua

Received: 14-06-2017
Revised: 05-07-2017
Accepted: 12-07-2017
specific analytical parameters to be considered, introducing small variations in the nominal conditions, and the statistical interpretation is performed by means of Student’s \( t \)-test or ANOVA test. Other wider alternative to determine the robustness of analytical methods is the Youden’s test. This test evaluates not only the method robustness but also highlights the effect of each analytical parameter in the final results. The basic idea of Youden’s test is not to study one alteration at time but to introduce several changes at once, in such a way that the effects of individual changes can be ascertained.

Captopril, 1-[(2S)-3-mercapto-2-merhyl-1-oxopropyl]-L-proline, (2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl] pyrrolidine-2-carboxylic acid, is a sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity.

The aim of the work was to evaluate the robustness of ultra-high-performance liquid chromatography (UHPLC) method for the quantitation of captopril, using Youden’s test, and determine the analytical parameters that present greater influence in the final results of the analysis.

**MATERIALS AND METHODS**

USP grade CPT and USP grade HCT were kindly donated by Darnitsa, Kiev, Ukraine. Solvents purchased from Merck, Darmstadt, Germany high-performance liquid chromatography (HPLC) grade. Tablets captopril was kindly provided by Ternofarm, Ternopil, Ukraine. Tablets captopres was kindly provided by Darnitsa, Kiev, Ukraine.

The chromatographic analysis of captopril performed on liquid chromatographs Agilent 1290 and HP 1100 systems. The columns used Nucleosil C18 (4.6 mm × 150 mm with a particle size of 5 \( \mu \) m) and Ascentis Express C18 Fused-Core\(^6\) technology (column size 4.6 mm × 150 mm with a particle size of 5 \( \mu \) m). The compounds were separated isotropically with a mobile phase consisting of methanol and 0.1% solution of trifluoracetic acid (40/60, v/v) at a flow rate 1.2 mL/min with injection volume 2 \( \mu L \). The effluent was monitored spectrophotometrically at wavelength 220 nm. Column temperature was 35\( ^\circ \)C.

**Standard Solution**

Primary stock solutions of captopril were prepared daily separately by dissolving 25 mg of each in 25 mL volumetric flasks (1.0 mg/mL) in mobile phase.

**Sample Solution**

The contents of 20 tablets contained to 25 mg of captopril were weighed individually, mixed, and powdered. Amount of the powder equivalent to two tablets content was weighed accurately, then transferred into 50 ml volumetric flask and diluted with mobile phase. Filtering of the sample solution was then carried out using 0.45 \( \mu \)m filters (Millipore, Milford, MA).

**RESULTS**

The robustness evaluation of UHPLC method for captopril quantitation was performed using the method proposed by Youdene Steiner. Seven analytical parameters were selected and small variations were induced in the nominal values of the method. Then, eight runs were performed with an aim to determine the effect of each parameter in the final result. The seven analytical parameters employed as well as the introduced variations are demonstrated at Table 1. The analytical conditions at the nominal values are represented by capital letters and the conditions with the small variation are represented by lowercase letters.

In each combination, three injections of each sample and standard solutions were carried out, at the work concentration. After the alteration of chromatographic column or mobile phase composition, there was a waiting of 30 min for system stabilization. The evaluated results in each combination were peak area, retention time (\( R \)), tailing factor (\( T \)), theoretical plates number (\( N \)), and captopril content.

For evaluating the effect of the column temperature in the final result of the analyses, the following equation was used:

\[
\text{Effect} \ C/c = (s + u + w + y)/4 - (t + v + x + z)/4
\]

Through the use of Youden’s test, it is possible to establish certainly the parameters which present higher influence in the final result of the analyses and perform a more rigorous control in the eventual variations of these parameters that may occur during a routine analysis.

**DISCUSSION**

In this study, our first trials were directed to find optimal chromatographic conditions, our objective of the chromatographic method development was to achieve a peak tailing factor <1.5, retention time in between 1 and 3 min, along with good resolution.\(^5,15\) In both equipments (Agilent 1290 and HP1100) were carried out simultaneously, the
assays for the robustness evaluation of the chromatographic method. The results obtained in the eight runs to captopril sample and standard solutions.

In Table 3, the effects of the parameter variations in the analysis results presented.

Using the criteria of Youden’s test, UHPLC method proved to be greatly robust regarding content of captopril, when variations in seven analytical parameters were introduced.\textsuperscript{[16,17]} The highest variation in captopril content was 0.96\% when was used column Nucleosil C18 (4.6 mm × 150 mm with a particle size of 5 µ). Relevant advancement in instrumentation and column technology were made to realize dramatic increases in resolution, speed and sensitivity of UHPLC/HPLC.

For the first time, a holistic approach involving simultaneous innovations in particle technology and instrument design was endeavored to meet and tackle the issues of the analytical laboratory. This was done to make analytical scientists more successful and businesses more profitable and productive.

Ascentis Express columns, based on Fused-Core particle technology, provide more than twice the speed and efficiency of traditional columns at half the backpressure of sub-2-µm
columns. Using column Ascentis Express C18 Fused-Core® technology (column size 4.6 mm × 150 mm with a particle size of 5 µ) decrease the retention time of captopril more than 2 times.

**CONCLUSION**

Youden’s test proved to be an efficient and helpful tool for the robustness evaluation of UHPLC method for assay of captopril in pharmaceuticals. Therefore, Youden’s test can be applied successfully for the robustness evaluation in validation process of analytical methods.

**REFERENCES**


17. Logoyda L. Validation of Chromatographic Methods of Analysis for the Determination of Active Pharmaceutical Ingredients in Different Medicines. Egypt: Pharma School Association for Pharmaceutical Development and Scientific Research; 2016. p. 34.

**Source of Support:** Nil. **Conflict of Interest:** None declared.